-
Mashup Score: 49Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma - 12 day(s) ago
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary…
Source: www.sanofi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma - 13 day(s) ago
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary…
Source: www.sanofi.comCategories: General Medicine News, Hem/OncsTweet-
Subcutaneous isatuximab is on the horizon! Press release on phase 3 IRAKLIA study shows s.c. similar to i.v. (as would be expected). Hopefully this will enable approval and availability of s.c. isatuximab soon! https://t.co/R395wFoGeg
-
-
Mashup Score: 7Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI - 3 month(s) ago
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved…
Source: www.sanofi.comCategories: General Medicine News, Allergy-ImmunologyTweet-
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI. https://t.co/ZzvV9Zbqwm https://t.co/1hH8vcMd5A
-
-
Mashup Score: 2
NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A ALTUVIIIO provides high-sustained…
Source: www.sanofi.comCategories: General Medicine News, PayerTweet-
Now published in @NEJM: pivotal phase 3 data highlighting treatment potential for children under 12 living with severe #hemophilia A. Learn more: https://t.co/0dSZNCRQfZ https://t.co/Fff9HEGr7D
-
-
Mashup Score: 0Global Hemophilia Survey: Patient Experiences & Needs - 9 month(s) ago
Sanofi’s global hemophilia survey assessed the needs, experiences, & attitudes of 2,700 patients, caregivers, & hematologists in 11 countries.
Source: www.sanofi.comCategories: General Medicine News, PayerTweet-
The answer? All three are major concerns for those living with hemophilia. Discover the full list and more insights from our survey with @HarrisPoll: https://t.co/gdl0uwTSVr #WorldHemophiliaDay
-
-
Mashup Score: 1US - 10 month(s) ago
In the United States we’re partnering with the Thurgood Marshall College Fund and Rutgers University Ernest Mario School of Pharmacy to foster a diverse and inclusive STEM community for students from underrepresented ethnic backgrounds. “Representation in healthcare is vital to ensure diverse perspectives, experiences, and needs are acknowledged and addressed, ultimately leading to more inclusive, accessible, and effective healthcare for all. “” Fostering diversity and representation in the healthcare
Source: www.sanofi.comCategories: General Medicine News, PayerTweet-
This #WomensHistoryMonth, in partnership with @RutgersU, we’re spotlighting our Sanofi NextGen Scholar Anabell Castillo who is driven to help pave the way for underrepresented voices in healthcare. Learn More: https://t.co/kuy1gv2tyd #AMillionConversations https://t.co/aehKxt3xTT
-
-
Mashup Score: 1US - 11 month(s) ago
In the United States we’re partnering with the Thurgood Marshall College Fund and Rutgers University Ernest Mario School of Pharmacy to foster a diverse and inclusive STEM community for students from underrepresented ethnic backgrounds. “Representation in healthcare is vital to ensure diverse perspectives, experiences, and needs are acknowledged and addressed, ultimately leading to more inclusive, accessible, and effective healthcare for all. “” Fostering diversity and representation in the healthcare
Source: www.sanofi.comCategories: General Medicine News, PayerTweet-
As a Sanofi NextGen scholar, Ifeoma is committed to creating a more inclusive healthcare system. Learn how we're supporting our next generation of healthcare leaders, like Ifeoma: https://t.co/jFDRDwBg11 #AMillionConversations https://t.co/JezHgSxPwz
-
-
Mashup Score: 47
Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant Sarclisa added to bortezomib,…
Source: www.sanofi.comCategories: General Medicine News, Hem/OncsTweet-
A timely great news before the start of #ASH23 isatuximab: Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant @TheIACH @SanofiFR @sanofi https://t.co/kHiIbKVzRm
-
-
Mashup Score: 47
Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant Sarclisa added to bortezomib,…
Source: www.sanofi.comCategories: General Medicine News, Hem/OncsTweet-
A timely great news before the start of #ASH23 isatuximab: Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant @TheIACH @SanofiFR @sanofi https://t.co/kHiIbKVzRm
-
-
Mashup Score: 4
Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo First and only biologic to show rapid and significant improvement in lung function (160 mL in FEV1) compared to…
Source: www.sanofi.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Love seeing these positive results for a drug being repurposed for #COPD! But we can’t just do this for on-patent drugs… we need to unlock the full potential of every @US_FDA approved drug to treat every disease possible! https://t.co/CCMHCAeDBK Join our mission @EveryCure !
-
Subcutaneous isatuximab is on the horizon! Press release on phase 3 IRAKLIA study shows s.c. similar to i.v. (as would be expected). Hopefully this will enable approval and availability of s.c. isatuximab soon! https://t.co/R395wFoGeg